Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
| Autor: | Maria Cosenza, Erika Roat, Alessia Bari, Monica Civallero, Stefano Sacchi, Luigi Marcheselli, Giulia Grisendi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
MAPK/ERK pathway
medicine.medical_specialty Indoles Lymphoma B-Cell Antineoplastic Agents Pharmacology chemistry.chemical_compound Enzastaurin Cell Line Tumor Internal medicine Indolent B – cell lymphoma Lenalidomide signaling pathways AKT MAPK Antineoplastic Combined Chemotherapy Protocols medicine Humans PI3K/AKT/mTOR pathway Cell Proliferation Hematology Cell growth business.industry Drug Synergism General Medicine medicine.disease Coculture Techniques Thalidomide Lymphoma chemistry Apoptosis Cancer research business medicine.drug |
| Zdroj: | Annals of Hematology. 91:1613-1622 |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-012-1490-6 |
| Popis: | Less toxic and more active treatments are needed for indolent lymphomas as there is no curative treatment, and patients eventually die due to complications related to their disease. The purpose of the present study was to assess the antitumour activity of the combination of low doses of Enzastaurin and Lenalidomide (Revlimid) on B-lymphoma cell lines. The combination of Enzastaurin and Lenalidomide, at doses as low as 1 μM, showed strong synergism against indolent lymphomas by reducing cell growth, producing an increase in G0-G1 phase followed by significant decrease in S phase, increasing apoptosis, and inhibiting PI3K/AKT, PKC and MAPK/ERK pathways. These preclinical findings, together with promising results obtained with Lenalidomide for the treatment of non-Hodgkin lymphoma, suggest that further evaluation of the combination of Enzastaurin and Lenalidomide for the treatment of indolent lymphomas is warranted. These compounds, with a favourable toxicity profile, are not classic chemotherapeutic agents, causing severe side effects, and could be considered an example of a new innovative attempt of an anti-cancer 'soft treatment'. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink